NICE has estimated that around 40% of people with COPD have elevated blood levels of eosinophils and, if half the eligible ...

Dupilumab, a simple pre-filled pen that people inject themselves with every two weeks, is the first biologic that targets both the symptoms of COPD and an underlying cause of the disease. It brings ...

Nearly 30,000 people in England living with chronic obstructive pulmonary disease could see their lives transformed after the ...

The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary disease ...

While COPD (chronic obstructive pulmonary disease) symptoms may start out as mild to moderate — with episodes of difficulty breathing that come and go — over time, COPD tends to get worse, and many ...

Chronic obstructive pulmonary disease (COPD) remains a substantial contributor to morbidity and mortality in the United States with an estimated 3.8% age-adjusted prevalence and 141,733 COPD deaths ...

People living with chronic obstructive pulmonary disease (COPD) typically rely on maintenance inhalers to manage their daily symptoms. They may also take rescue inhalers for sudden breathing ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The 2026 GOLD report newly highlights disease activity ...

In May 2025, the FDA approved mepolizumab (Nucala) as a treatment for chronic obstructive pulmonary disease (COPD). Before any drug gets near a pharmacy shelf, it starts with years of basic science ...

Adding mepolizumab to inhaled triple therapy significantly improved exacerbation outcomes compared with placebo in adults with chronic obstructive pulmonary disease (COPD), based on data from the ...